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Although monoclonal technology has done much to overcome the technical
problems of providing antibodies for the treatment of neoplastic disease, the
therapeutic effectiveness of antibodies in patients has been limited (1-3) . How-
ever, during this work several significant factors have been identified that may
thwart antibody attack on tumor cells . Prominent among these are: (a) the
presence of extracellular antigen that can block antibody access to tumor cells;
(b) the loss of antibody from the target cell surface due to antigenic modulation ;
(c) the apparent inefficiency with which natural effector mechanisms operate
with infused antibody ; and (d) the production ofan antiantibody response in the
patients .
A further problem, and one that is likely to become more prominent as the
potency of antibody treatment increases, is that of tumor heterogeneity . Any
variant tumor cell that can resist antibody attack, either because it lacks the
target antigen or is not susceptible to lysis by natural effectors, could, under the
selective pressure of antibody treatment, eventually emerge as the predominant
phenotype . Until recently such immunoselection had been seen only in animals
bearing tumors from long-established lines. Several groups demonstrated that
antigen-negative cells present in these transplanted tumors can escape attack
from therapeutic antibody (4, 5) or can survive in animals that have been
preimmunized against a tumor-associated antigen (6, 7) .
In clinical studies to date, tumors emerging in patients undergoing antibody
treatment have either expressed the target antigen in an unaltered state, or been
in a temporary state of antigenic modulation that reverted when the level of
therapeutic antibody subsided . Recently, however, Meeker et al . (8) reported
that 2 of 11 casesofhuman B cell lymphoma treatedwith monoclonal antiidiotype
(anti-Id) later developed variant tumors that were unable to react with the
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therapeutic antibody. The loss of reactivity appeared to stem from changes in
the amino acid sequence of the Ig heavy chain variable (V) region as a result of
point mutations in the gene (9). In a further study from the same group (10)
multiple overlapping idiotype subpopulations were defined in two cases of
follicular lymphoma before they had received any anti-Id treatment. Southern
blot analysis again suggested extensive somatic mutation in heavy chain genes.
An earlier report from Raffeld et al . (11) also found idiotypic variation in a
human lymphoma before anyanti-Idtreatment: here a variant subclone emerged,
unable to bind its anti-Id, after a transient spontaneous regression in the tumor.
Thus, although human B cell neoplasia may be monoclonal by conventional
criteria, they can still display variation in the structure of their Ig idiotypes.
Point mutations within the rearranged Ig V region occuras part of the normal
process that helps generate antibody diversity in the B cell repertoire (12).
Mutation frequencies within the V region DNA of responding B cells have been
estimated to be as high as one basepair per 10' per cell division, several orders
of magnitude above that quoted for many other eukaryotic genes (13, 14). It is
also known that similar random mutations can accumulate in the rearranged Ig
genes of certain myeloma and hybridoma cell lines (15). However these variants,
unlike those in normal B cell clones, probably gain no selective advantage as a
result of any structural changes in their Ig V regions, and consequently exist at
comparatively low frequencies (10-s-10-8) within such populations (15, 16). It is
now clear from the results discussed above that similar Ig variants can arise in
human B cell lymphomas, and that they may gain a selective advantage when a
change in their Id allows them to escape attack from anti-Id antibody. The
frequency at which new Ig variants will arise in such tumor populations is not
known, but the high mutational rate in normal B cells does not augur well for
the use of a single idiotope as a target for antibody attack.
The L2C lymphoblastic leukemia of strain 2 guinea pigs has proved a useful
model for those human B cell neoplasmsthat are likely to be amenable to therapy
with anti-Id. The major advantage of Ig Id as a target molecule is its tissue
specificity, which for all practical purposes will be limited to the neoplastic B cell
clone (17). One disadvantage has been that tumors under attack from anti-Id
have been particularly prone to antigenic modulation, to the extent that they
can become completely resistant to the cytotoxic actions of natural effectors in
vitro and in vivo (3, 18). A possible solution to this problem would be to couple
a toxin or similar molecule to the antibody to enable it to kill cells without the
host's effector systems. Such immunotoxins have been prepared in many labo-
ratories and have been shown to kill their target cells with great potency and
specificity (19).
In the present work we have used an immunotoxin composed of monoclonal
anti-Id and the ribosome-inactivating protein (RIP),' saporin, for the treatment
of the L2C tumor in guinea pigs. Saporin is one of a large group of single-chain
RIPS found throughout the plant kingdom (20). They resemble the A chains of
the plant toxins ricin and abrin in their ability to terminateprotein synthesis but,
' Abbreviations used in this paper:
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unlike these toxins, do not have a B chain by which they can bind to and enter
cells. The single-chain RIPS are therefore practically devoid of toxicity for intact
cells. Conjugation to an antibody bestows on them the ability to bind and enter
cells and shut down protein synthesis in much the same way as the A chain of
the toxins (21-23).
We now show that the treatment of L2C leukemia with anti-Id immunotoxins
although highly effective at destroying tumor and protecting tumor-bearing
animals, is usually thwarted by the emergence of variant tumors. These variants
are of two types: (a) cells that are surface Ig-negative due to a loss of heavy
chain production; (b) cells that express surface Ig, but with an altered Id that is
no longer reactive with the therapeutic anti-Id.
Materials and Methods
Leukemic Cells.
￿
The L2C lymphoblastic leukemia is maintained by in vivo passage in
strain 2 guinea pigs and has been described previously (24). Cells exhibit monomeric
surface IgMX (50,000 molecules/cell), and in short-term culture secrete free X light chain
together with small amounts of idiotypic 19 S IgM (25). L2C cells were isolated from fresh
leukemic blood on Ficoll-Hypaque (Lymphoprep; Nyeguard, Oslo, Norway) and were
always >98% viable by trypan-blue exclusion (26).
Production and Preparation of Antibodies.
￿
Polyclonal IgG antibody specific for mouse
normal IgG was prepared and conjugated with fluorescein isothiocyanate isomer I (BDH
Chemicals, Ltd., Poole, United Kingdom) (27). The FITC-labelled antibody showed no
detectable reactivity with L2C cells before they had been coated with mouse antibodies.
A panel of 16 mouse mAb, each specific for the L2C IgMX, has been used in this
investigation. The production of these antibodies and analysis of their interaction with
viable L2C cells has been described by Elliott et al (27). For the present work we have
retained the original numbering. 14 of the antibodies are specific for the Id of the L2C
IgM and were numbered sequentially, anti-Id-1-14, while two other antibodies, anti-X
and anti-A, are directed against constant regions of the guinea pig a light chain and A
heavy chain, respectively. The mAb anti-xId-9, although recognizing the L2C Id, shows a
limited crossreactivity for other guinea pig Ig (27, 28). A mouse IgGI mAb (M15-8)
showing no reactivity towards L2C cells was used for all control studies (control IgG I).
An additional mAb, anti-free X Id, was raised as described by Elliott et al. (27), using
urinary X chain isolated from L2C leukemic guinea pigs as the immunogen (29, 30). In a
standard ELISA (31), this antibody reacted strongly with L2C urinary X chains, weakly
with guinea pig normal X chain (29) and showed no reactivity with L2C idiotypic 19 S
IgM (32). Thus the epitope seen by anti-free X Id is expressed on X chain derived from
the L2C tumor, but is hidden or blocked in the intact IgM molecules. It appears also to
be present on a minor population of guinea pig normal X chains.
Monoclonal IgG was isolated from ascitic fluid that had been recovered from pristane-
primed (BALB/c x CBA)F, mice carrying the appropriate hybridoma cells as an ascitic
tumor. The IgG was first precipitated in 2 M ammonium sulfate in 0 .2 M Trizma base
(Sigma Chemical Co., St Louis, MO) and then chromatographed on Trisacryl-M-DEAE
(LKB-Produkter AB, Bromma, Sweden), with a linear salt gradient of 5-50 mM phos-
phate, pH 8.0, at room temperature. The antibodies eluted in this way were of high
purity by SDS-PAGE.
Immunofuorescence Studies.
￿
Binding ofmonoclonal antibodies to L2C cells was analyzed
by using the FAGS III Becton-Dickinson Electronics, Mountain View, CA). 2 x 10' cells/
ml in DMEM supplemented with 10% FCS, 2 MM L-glutamine, and 1 mM sodium
pyruvate (Gibco Europe, Uxbridge, United Kingdom) were treated with mouse mAb or
control IgG (5 Ag/ml) for 30 min on ice, washed and exposed to fluorescent rabbit anti-
mouse IgG at 0.5 mg/ml. After a final wash, cells were examined in the presence of
sodium azide (10 mM), which was added to prevent any modulation of surface-bound
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Fluorescent antibody-labelled cells were sorted using the FAGS III, and collected
directly into a 1 .5 ml plastic microfuge tube (Starstedt Laborartikel, Federal Republic of
Germany) containingsupplemented DMEM. Conditions for sorting were optimized using
glutaraldehyde-fixed chicken erythrocytes at a flow rate of 1,000 cells/s and a drop-drive
frequency of 37,000/s. Sorted cells were expanded by transfer into strain 2 guinea pigs
(5 X 105 cells/animal).
Preparation of Antibody-saporin Immunotoxin.
￿
Saporin was purified from the seeds of
Saponaria officinalis (soapwort) as described previously (33). It was coupled by disulfide
linkage to mouse monoclonal IgG using N-succinimidyl-3-(2 pyridyldithio) propionate
(SPDP). Conjugates eluting from gel filtration columns with an M, corresponding to
between 160,000 and 210,000 were used for the present work. They were found
predominantly to contain one molecule of antibody and one or two molecules of saporin
when analyzed as described by Thorpe et al. (23). The conjugate solutions were sterilized
by filtration through 0.22-Im filter, and stored at -70 °C after first freezing in liquid
nitrogen .
Uptake of [SH]Leucine by L2C Cells in Culture.
￿
Fresh L2C cells 5 X 106 cells/ml in
supplemented DMEM (see Immunofluorescence) were dispensed as 100-,l aliquots into
96-well flat-bottomed microplates (Gibco). Test samples ofimmunotoxin or diluted plasma
in the same medium (100,1/well) were then added and the plates were incubated at 37°C
in a humidified atmosphere of 5% C02 in air. After 3 h, cells were pulsed with 0.5
ACi/well [6H]leucine (TRK.510; Amersham International, Amersham, United Kingdom)
in supplemented DMEM for a further 6 h at 37°C in 5% C02. The incorporation of
[sH]leucine into L2C cells was assessed by harvesting the cells onto glass microfiber filters
using an automatic cell harvester (Dynatech, Billingshurst, United Kingdom). The radio-
activity retained on the filters after washing with water was measured in 1 ml of Cocktail
T liquid scintillant (BDH Chemicals Ltd.) using a LKB/Wallac liquid scintillation counter,
1216 Rackbeta (LKB Produkter, Bromma, Sweden). All experimental points were deter-
mined in triplicate. The concentration of immunotoxin that inhibited [ H]leucine uptake
by 50% (the IC50 value) was calculated as described by Thorpe et al. (23).
Blood Clearance of Unconjugated and Saporin-conjugated Antibody.
￿
Male strain 2 guinea
pigs were injected intravenously with 140,ug per 400 g body weight ofantibody aloneor
antibody conjugated to 30 wg of saporin in PBS. At various intervals duplicate blood
samples (50 u1) were taken in heparinized capillary tubes from the ear vein and diluted
into 200,ul ofsupplemented DMEMcontaining25 U/ml heparin (Weddel Pharmaceuticals
Ltd., Wrexham, United Kingdom). After centrifugation at 500 g for 5 min, the superna-
tant was removed for assessment of antibody and immunotoxin content.
Antibody activity was measured in a standard ELISA as described by Stevenson et al.
(31). Briefly 96-well microplates were coated with L2C Id IgM at 100 ng/ml in sodium
carbonate buffer, pH 9.6. After blocking with 1 % BSA in PBS and washing, 100 wl
aliquots of antibody standards (1-200 ng/ml) or diluted test samples were added, and
bound mouse Ig detected by exposure to appropriately diluted horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse Ig (Nordic Laboratories Ltd., Maidenhead, United
Kingdom).
The level of biologically active immunotoxin in the circulation of guinea pigs was
assessed by measuring the ability of plasma samples to inhibit the incorporation of [5H]-
leucine into cultured L2C cells as described above. The reduction in [5H]leucine uptake
induced by each plasma sample was compared with that induced by a range of immuno-
toxin standards to estimate the level ofbiologically active immunotoxin in the circulation.
Immunoglobulin Secretion by Cells in Culture.
￿
Fresh leukemic cells were suspended in
supplemented DMEMat 2.5 X 106 cells/ml and incubated at 37 °C in 80-cm' tissue culture
flasks (Gibco) in a humidified atmosphere containing 5% C02 in air. Samples of the
supernatant were taken at intervals, cooled on ice, and the cells sedimented by centrif-
ugation at 200 g for 5 min. The concentration of guinea pig Ig in the supernatants was
estimated by ELISA using the method described by Stevenson et al. (31). The IgM was
captured from supernatant samples by adsorption binding to sheep anti-Fdu (32) that had
been coated onto microplates at 20 Ag/ml and then detected with HRP-labelled sheep
anti-,u chain antibody (31) at 4 ug/ml. Free guinea pig X chain and IgM, both bearing theGLENNIE ET AL.
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L2C Id, were quantified in similar assays, but using monoclonal anti-free a Id and anti-
Id-3, respectively, coated to the plate at 5 ug/ml, and then detecting the bound guinea
pigIgwithanappropriatelydiluted HRP-labelled goatanti-guineapig globulinantiserum
(Nordic Laboratories Ltd., Maidenhead, United Kingdom). Standard solutions ofguinea
pig normal IgM (32), purified idiotypic IgM (25), and L2C urinary X chain (34) were
included in all assays, over a concentration range of 1-200 ng/ml.
Immunotherapy Studies.
￿
Groups ofage-matched strain 2 guinea pigs (400-450 g) were
inoculated intraperitoneally with 10' L2C cells (day 0). The doubling time of our L2C
tumor line is ^-19 h, and without treatment animals die 13-15 d later. At this time the
white blood count is ^-250,000 cells/1I and the animals have extensive tumor deposits in
the liver, lymph nodes, bone marrow, andparticularly in thespleen. Treatment wasgiven
as a single intraperitoneal or subcutaneous injection on day 1 (unless stated otherwise),
and consisted of specific immunotoxin, or of control reagents. Survival was monitored
daily and expressed as a mean survival (days) for each group ofanimals. For the purposes
of this calculation, the survival time of animals that did not develop tumor within a 100
dwas taken as the last day on which a death occurred within that group.
Results
Toxicity and Specificity of Immunotoxin for L2C Cells in Culture.
￿
Saporin has
been conjugated to three IgGI mAb for the present work. Two of these, anti-
Id-1 and -3, are specific for the L2C IgM Id and have previously been shown to
have association constants at 37'C of 1.1 X 109 and 2.3 X 10'/M, respectively
(27). The third antibody was a control IgG1 of irrelevant specificity and showed
no binding to L2C cells. The toxicity of saporin-containing immunotoxins was
assessed according to theirability to inhibit the incorporation of[sH]leucine into
protein by L2C cells in vitro.
Fig. 1A shows that both the anti-Id containing immunotoxins were highly
toxic, halving the uptake of[8H]leucine (IC5o) at a concentration of 4-8 X 10-11
M. In contrast, the IC5o for the control IgG-saporin conjugate and for free
saporin were 2.8 X 10-8 M and 4.7 X 10-7 M (extrapolated value) respectively,
indicating their comparative lack oftoxicity. Saporin coupled to the control IgG
was always 5-10-fold more toxic than free saporin, as shown in this experiment.
The high level ofspecificity indicated by toxicity results was confirmed using
an L2C variant, LIO1, which expressed normal levels of surface IgMX with a
mutant Id (described fully later) still recognized by anti-Id-3 but not by anti-Id-
1 . Fig. 1B shows that this change in reactivity is accompanied by a corresponding
change in sensitivity to the immunotoxins. The anti-Id-3 immunotoxin remained
fully toxic for the variant cells (IC5o 2.2 X 10-10 M), while the nonreactive anti-
Id-l-saporin conjugate had the same low toxicity as the control IgG immuno-
toxin.
Throughout this work, treatment of L2C cells with anti-Id alone had no
significant effect on [8H]leucine uptake . Furthermore a mixture ofantibody and
free saporin, in proportions that matched those in the conjugate, was no more
toxic than free saporin (Fig. 1A).
Blood Clearance ofUnconjugated and Saporin-conjugated Antibody.
￿
A small dose
(140 Ag) of unconjugated anti-Id-3 antibody (assayed as anti-Id antibody) disap-
peared from the plasma ofguinea pigswith ahalf-life of40 h (Fig. 2). In contrast,
a similar quantity of the same anti-Id coupled to saporin (assayed as biologically
active immunotoxin) was clearedmore quickly, withthe curveappearingbiphasic.
During the first phase the level of functional conjugate in the plasma fell away48 IMMUNOGLOBULIN VARIANTS AFTER TREATMENT OF B CELL TUMOR
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FIGURE 1 .
￿
Uptake of ['H]leucine by wild-type L2C (A) and an idiotope-loss variant of L2C,
LIO1 (B), in culture. Cells (5 X 106 cells/ml) in supplemented DMEM were exposed to free
saporin (X), control IgG-saporin (/), anti-Id-l-saporin (A), or anti-Id-3-saporin (0) at the
concentrations of saporin shown for 3 h at 37°C before pulsing with ['H]leucine (6 h), and
then harvesting the incorporated radioactivity. Points representgeometric means oftriplicate
determinations. Nonconjugated antibodies were without significant effect of ['H]leucine
uptake.
rapidly (half-life, 1-3 h), until at 6 h only ^-10% ofthe initial conjugate remained.
During the second phase this remaining 10% was cleared, but with a longer half-
life of between 15 and 17 h (Fig. 2). By 50 h, circulating immunotoxin was
generally present at <1% of its initial level. Unconjugated saporin can be
expected to be cleared with a half-life of approximately 10 min (Stirpe, Derenzini,
and Berbieri, manuscript in preparation).
Therapeutic Performance of Anti-Id Antibody and Anti-Id-Saporin Conju-
gates.
￿
Both the anti-Id antibodies (anti-Id-1 and -3) when given as unconjugatedGLENNIE ET AL .
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FIGURE 2 . Blood survival of noncon-
jugated anti-ld-3 (/) and anti-Id-3-sa-
porin conjugate (0) in strain 2 guinea
pigs. After intravenous infusion of 140
ag antibody, plasma samples were taken
at the times indicated and assessed for
anti-Id antibody (/ ; determined by
ELISA) or for the levels of functional
immunotoxin (/; determined by the abil-
ity of plasma samples to inhibit ['Hl-
leucine uptake by L2C cells) . The bar at
each point represents values determined
fortwo animals (samples taken in dupli-
cate) . The levels of functional immuno-
toxin in the circulation proved difficult
to determine and are subject to consid-
erable error, but the actual rate ofclear-
ance probably lies within the range in-
dicated (shaded area) .
FIGURE 3 .
￿
Immunotherapy with unmodified anti-Id mAb . Groups of 10 guinea pigs were
inoculated intraperitoneally with 10 5 L2C cells (day 0) . After 24 h they were injected subcu-
taneously with 150 wg (A) or 1 mg (B) of control IgG (0), anti-ld-1 (A), or anti-Id-3 (Q) .
Survival was recorded daily.
preparations were able to prolong the lives ofL2C leukemic guinea pigs . Fig . 3B
shows that a single subcutaneous injection of anti-Id-1 (1 mg) given 24 h after
an intraperitoneal inoculum of 105 L2C cells increased the mean survival of
animals from 14 .8 d to 20 d. Anti-Id-3, although protective at 1 mg/animal in
leukemic guinea pigs, was consistently less effective than anti-Id-l . Treatment
with smaller quantities of either antibody yielded progressively less protection
down to a level of ^-150 ,ug/animal, at which point no increase in survival was
seen (Fig . 3A) .
Conjugation with saporin greatly improved the antitumor activity of the two
anti-Id antibodies . In parallel experiments to those described above, the subcu-
taneous administration of only 140 Ag of either antibody conjugated to ^-30 ug
of saporin extended the mean survival time of animals from 15 .3 d in control
animals to 30 .5 and 30.8 d (Fig . 4A) . In these experiments, unlike those using
the unconjugated anti-Id antibodies (Fig . 3B), the two anti-Id conjugates per-
formed equally . Other control groups evaluated in this investigation but not50 IMMUNOGLOBULIN VARIANTS AFTER TREATMENT OF B CELL TUMOR
FIGURE 4. Immunotherapy with immunotoxins. Groups of guinea pigs were inoculated
intraperitoneally with 105 L2C cells (day 0). After 24 h they were injected subcutaneously (A)
or intraperitoneally (B) with 170 Wg of control IgG-saporin conjugate (/), anti-Id-I-saporin
conjugate (A), or anti-Id-3-saporin conjugate ("). Two othergroups were treated with 1 mg
of control IgG (p) or with 30 jAg of free saporin (X). Survival was recorded daily.
shown in Fig. 4A included animals treated with free saporin (30 tig/animal), anti-
Id alone (150 ,ug/animal), or a mixture offree saporin and unconjugated anti-Id
given in the aboveproportions. Alltreatmentswere withoutsignificantprotection
against the leukemia, with mean survivals between 14 and 17 d.
Throughout these immunotherapy trials the L2C cells and the immunotoxins
were introduced atseparate sites, usingintraperitoneal and subcutaneous routes,
respectively. When the immunotoxins and the tumor were both injected into the
peritoneum, some protection was conferred by the control immunotoxin. Fig.
4B shows that in animals given the specific anti-Id immunotoxins the increase in
mean survival remained unaltered at almost 14 d, while in those receiving
conjugates containing control IgG it was increased from the usual 14 d to just
over 20 d. Other control groups including those receiving free saporin or
unconjugated control IgG via the peritoneum were not protected in this nonspe-
cific manner (Fig. 4B).
Emergence of Ig- L2C During Therapy.
￿
Immunoglobulin expression on L2C
cells that emerged in guinea pigs after therapy was examined by cytofluorimetry
usingthe FACS III. Leukemic cellsrecovered from animals that hadbeen treated
with control IgG alone, anti-Id antibody (1 mg/animal), or control IgG conju-
gated to saporin (Fig. 4) all had the normal Ig profile (Fig. 5A): strong reactivity
by indirect immunofluorescence with anti-X chain, anti-A chain, and both anti-
Id antibodies. In contrast, 16 ofthe 19 animals treated with the anti-Id-saporin
conjugates developed tumors that were completely negative for both surfacea
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FIGURE 5. Expression of surface
IgMX on leukemic cellsemerging after
immunotherapy treatments described
in Figs. 3and4. Cells(2 X 10'cells/ml)
were exposed to anti-ti mAb (5,ug/ml)
and, after washing, bound mouse an-
tibody was detected by fluorescent
rabbit anti-mouse Ig. Three profiles
of Ig expression were detected by cy-
tofluorimetry: A, cellsrecovered from
animals treated with control IgG (Fig.
3), unmodified anti-Id (Fig. 3), free
saporin, or the control IgGsaporin
conjugate (Fig. 4A); B, cells recovered
from 16 of the 19 animals treated with
the two anti-Id-saporin conjugates
(Fig. 4A); and C, mixed cell popula
tions recovered from 2 of the 19 animals treated with the anti-Id-saporin conjugate. Values in
parentheses alongsideeach cell population represent themean fluorescence intensity(arbitrary scale:
0-250) of that population. Similar training profiles were obtained using anti-a and anti-ld mAbs
(data notshown).
Logof fluorescence intensity
IgMX and Id (Fig. 5B). Furthermore, this negativity was maintained during
short-term culture in vitro (24 h) and forsix serial passagesin vivo, demonstrating
that it cannot be attributed to modulation. The remaining two animals in which
tumor developed from this group showed a mixture of surface Ig-negative and
-positive cells. The positively staining cells also reacted with anti-Id antibodies.
A typical surface Ig profile from one of these animals is shown in Fig. 5C. At
this point the Ig- variants were designated RN (receptor negative).
The RN cells were next investigated with respect to their production and
release of Ig during short term culture in vitro. Serial supernatants were taken
and assayed by ELISA for guinea pig IgM, free X chain carrying the L2C light
chain Id, or Ig with the intact L2C Id composed ofthe combined heavy and light
chain. Fig. 6 shows that, unlike the wild-type L2C, RN cells release no p chain
and consequently no intact idiotype into the supernatant. They do, however,
secrete normal or even elevated levels ofidiotypically intact X chains.
The loss of Ig p, chain from RN cells was confirmed by showing that acetone-
fixed cytospin preparations of RN cells were also negative when stained by the
immunoperoxidase technique for intracellular ,u chain. In addition, RN cells,
consistent with their lack of surface Ig, were extremely resistant to the toxic
effects of anti-Id-containing immunotoxins in vitro. Treatment of the cells with
the immunotoxins at concentrations approaching 10-6 M reduced their [sH]-
leucine incorporation by only 20-30%.
Emergence of Ig Variants after Immunotoxin Treatment In Vitro.
￿
To investigate
further the heterogeneity of the L2C leukemia with respect to Ig expression,
fresh cells (2 X 107 cells/ml) in supplemented DMEM were treated in vitro (2 h
at 37'C) with the various immunotoxins (2 Ag/ml) and were then given to
untreated guinea pigsasanintraperitoneal inoculum of4 X 107 cells. The treated
L2C cells remained >95% viable by trypan blue exclusion at the time of inocu-
lation and were injected without washing; each guinea pig thus receiving ^-4 Ag
of immunotoxin along with the cells. Table I shows that animal survival was52 IMMUNOGLOBULIN VARIANTS AFTER TREATMENT OF B CELL TUMOR
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None
Anti-Id-I-saporin*
Anti-Id-3-saporin*
FIGURE 6. Immunoglobulin secretion by the wild-
type L2C cells (solid lines) and the surface Ig-negative
variant, RN (broken lines). Cells were cultured (37°C)
at 2.5 X 106 cells/ml in supplemented DMEM, while
aliquots ofsupernatant were takenat thetimesshown.
Levels of free idiotypic X chain (/) and u chain (0)
were measured by ELISA. Anti-Id-3 antibody was
used in an additional ELISA to measurethe intact Id
formed by the combined to and X chains. However,
for clarity, the resultshave notbeen included because
they simply confirmedtherelease of intact IgMX from
wild-type L2C (25) and showed that RNO1 cellsfailed
to secrete detectable levels of intact Id.
TABLE I
Mean survival (range)
d
13 .7 (13-15)
25(22-27)
23.8 (23-25; one long-term survivor)
Matched groups ofguinea pigs were given 4 X 107 treated L2C cells as
an intraperitoneal inoculum on day 0, and survival times were recorded
daily. Forall groups, n = 5animals.
* Cells at 2 X 107 cells/ml in supplemented medium were treated in vitro
for 2 hat 37 °C with theanti-Id-saporin conjugates at 2 mg/ml.
extended by -10 d as a result of in vitro treatment, with one long-term survivor
in which tumor failed to develop.
The predominant cell type (70-90%) to emerge in all these animals was
completely negative for surface IgMX and Id (Fig. 7), resembling the RN variant
we had seen in our previous immunotherapy experiments with anti-Id-containing
immunotoxins (Fig. 4). In addition to the RN cells, eight of the nine animals in
which tumor developedalso carried a minorpopulation (4-26%) of cells express-
ing surface IgMX (IgMX'). However, in contrast to the IgMX+ cells emerging in
the previous experiments, these cells did not react with the therapeutic anti-Id
antibody. Fig. 7 shows twosuch examples, which are typical ofthe cells recovered
from the eight guinea pigs. In the first (Fig. 7A), ^" 18% of the emerging L2C
express surface IgMX, but the majority of these cells were unable to bind either
of the anti-Id antibodies. Such cells probably represent a variant population of
L2C with a IgMX+/Id-3-/Id-1 - phenotype; i.e., an idiotope-loss variant. A small
number of cells (<2%) could be detected within this tumor sample that bound
both anti-Id antibodies . These are probably residual phenotypically wild-type
L2C that survived the in vitro treatment with saporin conjugate.a
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FIGURE 7.
￿
Expression of surface Ig on cells emerging in animalsgiven in vitro-treated L2C.
Fresh L2C cells (2 x 107 cells/ml)were treated with immunotoxins (2 ug/ml) for 2 h at 37°C
as shown in Table I, and then inoculated into untreated strain 2 guinea pigs (4 x 107
cells/animal). Emerging leukemic cells were stained by indirect immunofluorescence using
anti-X, anti-I, anti-Id-1, and anti-Id-3 followed by fluorescent rabbit anti-mouse Ig, before
analyzingon theFACS III. Twotypical staining profiles arerepresented from thenine animals
that developed tumors (Table I): A, cells treated with anti-Id-3-saporin conjugate; B, cells
treated with anti-Id-l-saporin conjugate. Values in parentheses indicate the percentage of
cells staining with each antibody.
The second example in Fig. 7 (B) again shows a predominantly IgMX- tumor
(75%) that contained a minority population of L2C that expressed surface IgMX
(23-25%). However, in this example a similar proportion of cells (23%) also
reacted with the anti-Id-3 antibody, while only 9% were able to bind anti-Id-1.
These results point to the existence of at least two types of IgMx' L2C within
this tumor: first a population of the cells (9%) that were recognized by both anti-
Id antibodies, and which probably represent wild-type L2C cells not destroyed
by immunotoxin treatment; the second is a population representing ^-14% of
the tumor, which expressed the determinant seen by anti-Id-3 but not that
recognized by anti-Id-1 (Id-3+/Id-1-). These Id-3i'/Id-1 - cells were recovered in
four of the five animals that received tumor treated with the immunotoxins
containing anti-Id-1 (Table 1). The reciprocal phenotype, ld-3-/Id-1', was not
observed after treatment with the anti-Id-3-saporin conjugate. This latter treat-
ment yielded only the IgM+/Id-3-/Id-1- variant shown in the first example.
Isolation of Idiotope-loss Variants.
￿
The tumors that emerged containing Ig
and idiotope-loss variants were each passaged without further treatment for one
generation in guinea pigs. They were then labelled by indirect immunofluores-
cence using anti-a and anti-A, antibodies, together with a panel of 14 different
anti-L2C antibodies. All tumors retained their altered Ig phenotypes, but the
proportion of IgMX+ cells was increased to almost double, suggesting that these
cells have greater vigor. Fig. 8 shows a typical example of the staining profile
obtained with these passaged tumors. These particular cells correspond to those
shown in Fig. 7A. The bulk of the tumor remained Ig (RN), but the proportion
of IgMX'' cells increased from -17% on first emerging (Fig. 7A), to ^-30% in the
second guinea pig. Although 10 of the 14 anti-ld antibodies, including anti-Id-1
and -3, showed no significant labelling of these cells, the remaining 4 stained a
similar proportion to the anti-X and anti-A antibodies. Note that those cells that
(18) (16) (<2) (<2)
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FIGURE 8. Identification of idiotype-loss
variants emerging in animals given in vitro-
treatedL2C.The leukemic cells shown in Fig .
7A were passaged in a single untreated guinea
pig before being analyzed by indirect immu-
nofluorescence using monoclonal anti-X and
anti-A, together with a panel of 14 anti-L2C
IdmAbs (anti-Id-1-14) . Values in parenthesis
indicate the percentage of cells staining with
individual mAbs .
FIGURE 9.
￿
Variants (LIO1-6) isolated from tumors emerging in guinea pigs given immu-
notoxin-treated L2C (Table I) were characterized with respect to their reactivity with anti-.N
and anti-A mAb together with a panel of 14 anti-L2C-Id antibodies . Indirect immunofluores-
cence staining was measured on the FACS III. Numbers are mean fluorescence intensity
(arbitrary scale: 0-250) for each antibody-variant reaction . The shaded bars represent the
intact L2C IgM Id, loss of recognition by a particular antibody (mean fluorescence intensity
<50) is indicatedby an unshaded box in the bar .
reacted with anti-Id-13 could be subdivided into at least two populations : those
which stained strongly and those which stained weakly .
Using the reactive anti-Id antibodies for each of the passaged tumors, the
idiotope-loss variants were stained and then sorted on theFACS 111 . The isolated
cells were expanded in untreated guinea pigs before being resorted and passaged
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in guinea pigs . In this way, six distinct idiotype-loss variants (LIOI-6) were
eventually isolated to homogeneity, each showing a different reaction profile
with the panel of antibodies (Fig. 9) . At the extremes of these reaction profiles
were LIO1, which retained reactivity with 11 of the 14 antibodies, and L106,
which bound only 3 . While certain variants appear to retain reactivity with
antibodies, the intensity of the staining was sometimes well below average . A
good example of this was the labelling of LI05 cells with anti-Id-13 . This
antibody binds to LI05 cells, but with a mean fluorescence intensity approaching
halfits usual level . These particular cells can alsobe seen before they were sorted
as the weakly staining population 51d- 13 of Fig . 8 .
Despite careful analysis, we have not isolated cells that express Ig with a
completely novel idiotype, i.e ., which fail to react with any of the anti-ld
antibodies in the panel .
Discussion
The covalent linkage of the RIP, saporin, to anti-Id mAb has been shown to
generate highly potent and specific reagents . Both the anti-Id antibodies (anti-
Id-1 and anti-Id-3) have produced immunotoxins that were toxic for L2C cells in
vitro at concentrations below 10- ' ° M (IC5o = 4-8 X 10"), while those contain-
ing a control IgG showed little toxicity unless added at concentrations above
10-7 M . The high degree of specificity was confirmed using an Id variant of the
L2C tumor that was recognized by anti-ld-3 but not by anti-Id-1 .
It is known that the binding affinities of the two therapeutic anti-Id antibodies
we have used differ by a factor of 10 (see Results) ; however this difference does
not seem to have influenced the specific cytotoxicity of the immunotoxins in
vitro . Other workers (22) have found that cytotoxic potency increases as the
affinity of the antibody component increases . It is possible that the lower-affinity
immunotoxin used in the present study recognized an epitope that was particu-
larly favorable for immunotoxin activity, for example, one that encouraged the
immunotoxin to enter the cell via endocytic vesicles (27), or one that positioned
its RIP component in close proximity to the membrane it must traverse .
The short metabolic survival of our immunotoxins in guinea pigs compared
with that of the nonconjugated antibody was not unexpected . Other workers
have found that conjugation of proteins, including RIPS, to antibodies consid-
erably reduces their survival in the circulation (35-37) . In the present studies we
have shown that ^"5% of the initial levels of functional anti-Id-saporin conjugate
remained in the plasma at 24 h, and that cytotoxic levels (>10- ' ° M) were
detectable for -2 d after the infusion of 350 1Ag/kg body wt . Similar results have
been reported by Letvin et al . (36) after administration ofmonoclonal anti-T I I-
saporin and -gelonin conjugates to rhesus monkeys . They found that in the
initial decline phase, the circulating levels of intact immunotoxins dropped to
-r10% of their original levels . Thereafter cytotoxic immunotoxin remained
detectable in the plasma for up to 3 d .
At least two factors are known to limit the survival ofimmunotoxins in animals
and probably also in man : first, the rapid removal by the liver, the organ in
which most toxicity has been reported ; and second, the breakdown of the
disulfide linkage between the antibody and the RIP . The accumulation in the56 IMMUNOGLOBULIN VARIANTS AFTER TREATMENT OF B CELL TUMOR
liver has been a particular problem for those RIPS such as ricin A chain, which
are naturally glycosylated. Specific hepatic receptors for carbohydrate residues
(such as mannose) can remove these compounds very effectively, giving them
very little chance to circulatein theplasma (37) unless they are first deglycosylated
(38). Saporin does not suffer from this problem, as it is free of carbohydrate
(33), but nevertheless when linked to IgG or F(ab')2 it still accumulates in the
liver, where considerable toxicity may result (Stirpe, Derenzini, and Berbieri,
manuscript in preparation). The lack of stability in the disulfide linkage between
the antibody and RIP is also a problem with immunotoxins prepared using
commercially available crosslinking agents, such as SPDP and 2-iminothiolane
(36, 38). Recently this problem has been tackled by thesynthesis of new disulfide
coupling agents that form immunotoxins relatively stable in vivo (Wallace and
Thorpe, ma(iuscript in preparation).
Therapeutically, the anti-Id immunotoxins used in the present study have
proved potent agents. A single dose of immunotoxin extended the lives of
leukemic animals by ^-15 d. Unmodified anti-Id antibodies have never ap-
proached this level of protection in the L2C leukemia (39). We have shown in
the present work that the maximum increase in mean survival seen with mouse
mAbs was ^-5 d (Fig. 3B). The proportion of the L2C inoculum destroyed during
such treatment cannot be measured accurately. It might be assumed that, with a
doubling time of -19 h, a 50% reduction of the tumor load would protect
animals carrying the L2C leukemia for this period. Thus, any treatment that
provides an extra 15 d survival will probably need to destroy all but a minute
fraction of the initial tumor inoculum. Indeed, if we omit complicating factors
from our calculations, such as changes in the doubling time of the tumor during
its development, then it can be estimated that only one cell need escape the
immunotoxin treatment. This estimate accords with the results of Thorpe et al.
(23), who showed that a single injection ofan anti-Thy-1 .1-saporin immunotoxin
into mice bearing a Thy-1.1-expressing lymphoma extended the survival times
of the animals by the extent expected if 99.999% of the tumor cells had been
destroyed. Similarly, in an earlier study, Vitetta and colleagues (40) showed that
mice with advanced B cell lymphoma (BCII) could be rendered free of apparent
disease by splenectomy, total lymphoid irradiation, and treatment with an im-
munotoxin composed of anti-IgD antibody and ricin A chain. The surviving
mice, however, harbored a number of dormant tumor cells that could induce
lymphoma when transplanted into naive recipients (41). Several other groups
have also shown impressive antitumor effects with immunotoxins, but in almost
all cases animals have not been entirely cleared of disease (19).
Ig phenotypes of the cells emerging after therapy with immunotoxins are
summarized in Table II. Tumors emerging in leukemic animals that had been
treated with anti-Id-saporin conjugate were predominantly (16 of 19 animals)
IgMX- (Table II, protocol A). This phenotype was not due to chronic modulation
of cells in the treated animals, as it was maintained during short-term culture in
vitro and stable through six serial passages in untreated animals. Furtheranalysis
of the Ig production by these cells, which we have termed RN, revealed them to
be u heavy chain-loss mutants of the L2C line, which neither expressed nor
exported intact IgM. Their Ig loss did not extend to the X light chain, which wasGLENNIE ET AL .
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TABLE 11
Summary of Tumor Variants Arising after Anti-Id Immunotoxin Treatment
Cell population
Protocol
Cells inoculated into each
￿
10 5 (untreated)
￿
4 X 107 (cells pretreated with
guinea pig
￿
anti-Id-saporin)
Treatment of tumor-bear-
￿
Anti-Id-saporin (170 ug/ani-
￿
None
ing animals
￿
mal)
Emerging tumor cells
￿
Majority surface Ig-negative
￿
Majority surface Ig-negative
Small minority surface Ig-
￿
Minority surface Ig-positive
positive (Id-intact)
￿
(Id-mutated)
Small minority surface Ig-posi-
tive (Id-intact)
In protocol A, guinea pigs that received L2C cells (intraperitoneally) 24 h previously were treated
with a single subcutaneous injection of anti-Id immunotoxin (170 wg/animal), while in protocol B,
fresh L2C were exposed to the anti-Id immunotoxin (2 kg/ml) for 2 h in vitro (37 ° C) before being
transferred into guinea pigs.
secreted normally as free molecules with a light chain idiotype characteristic of
the parent tumor .
A number of animal studies have demonstrated that immunological pressure
on a tumor can result in the outgrowth of stable variants that lack the target
antigen . This event has been described in at leasttwo situations : in tumor-bearing
animals that have been previously immunized with the tumor (7) or with an
appropriate antigen derived from the tumor (6); and after passive serotherapy
with specific antitumor antibody (4, 5) . In the L2C model, despite some highly
significant tumor protection, neither of these approaches has yielded stable L2C
variants . Stevenson and Gordon (42) showed that the leukemias that emerged in
guinea pigs that had been preimmunized with L2C derived idiotypic IgM were
often negative for surface IgM . However this phenotype resulted not from a
tumor variant but from antigenic modulation, which was reversed on removal
of the immunological pressure either by culturing cells in vitro or passage in
naive animals . Similarly, multiple infusions of an anti-Id mAb given to animals
bearing this tumor also yielded cells that had modulated their surface IgM, a
condition they maintained only while excess antibody persisted in the animals to
perturb the turnover of newly synthesized surface IgM molecules (43) .
The emergence of RN as a stable IgM- variant(s) of the L2C implies that the
current immunotoxin therapy has imposed a greater selective pressure on this
tumor than our previous regimens . This increased potency probably stems in
part from the fact that antigenic modulation does not offer an effective means
of escape to tumor cells, and may actually aid their destruction by channelling
the saporin into the endosomes (44, 45) . The frequency at which RN cells exist
in the L2C population is unknown . Clearly it is well above 10-5 , because all but
1 of the 19 animals treated developed tumors that were totally (16 animals) or
partially (2 animals) composed of RN cells . Further studies are underway to58 IMMUNOGLOBULIN VARIANTS AFTER TREATMENT OF B CELL TUMOR
establish this frequency and also to show whether RN cells can arise continuously
in the L2C tumor.
The second type of Ig variant to be selected by immunotoxin treatment
expressed normal levels ofsurface IgMX, but failed to react with the monoclonal
anti-Id used in the therapeutic conjugate; i.e., they were idiotope-loss variants.
Such cells must be at a very low frequency in the wild-type L2C population,
because they only became apparent after the in vivo passage of a large tumor
inoculum (4 x 107 cells) that had been preexposed to an immunotoxin in vitro
(Table II, protocol B). Careful analysis and sorting by cytofluorimetry using a
panelofanti-Id mAbs allowedsixdistinct and stable idiotope-loss variants (LIO1-
6) to be isolated. Each reacted with anti-A and anti-p, antibodies together with
various combinations of anti-Id in the panel, but failed to bind the particular
anti-Id (anti-Id-1 and/or -3) from which they had escaped during treatment. A
wide spectrum ofreactivity was observed, from LIO1 which bound 11 of the 14
anti-Id, to RN06, which reacted with only 3.
These changes in idiotype expression appear analogous to those described by
Meeker et al. (8) in two cases of B cell lymphoma receiving treatment with
unmodified anti-Id antibody. In both situations the emerging tumors have failed
to recognize the antibody that was used in treatment, despite the continued
expression of surface Ig and the apparent monoclonal origin of these tumors.
The Stanford group have pointed toextensive point mutations inthe IgV region
of one of these tumors (9) and also in many other B cell neoplasms (Levy, R.,
personal communication) as an explanation for their loss ofrecognition by anti-
Id antibody. Asimilar explanation for our current observation in the L2C tumor
would also implicate several changes in the V region sequence in order that at
least six and probably more new idiotypes could be generated. However, alter-
native mechanisms may also exist in which more extensive changes in the Ig Id
could occur. Studies in hybridoma cells (16), and recently with the chicken X
light chain V gene (46) have shown that whole segments of the V region DNA
in a rearranged V gene can be replaced by that of neighboring V regions to
generate new sequences. We suspect that such transpositions would introduce
quite major structural alterations into all or at least a major part of the Ig V
region. Our present work indicates that many of the changes in idiotype are
quite subtle: first because some idiotope-loss variants retain activity with almost
all the anti-Id antibodies (LI01 and 2), and second because occasionally anti-Id
antibodies bind with a reduced intensity to individual variants compared with
their activity against the original tumor, suggesting that the idiotope remains
with very minor changes. The exact mode and extent ofchanges in the V region
sequence will only emerge when the L2C and its variants have been fully analyzed
at the level of the DNA.
The current work underlines the potential problems facing the Ig Id as a
target for the treatment of B cell malignancies. As the selective pressure from
antibodies is increased, perhaps by avoiding antigenic modulation or by using
immunotoxins that circumvent this primary escape route, the next major mech-
anism oftumor escape becomes variants that have lost or mutated their Ig. Most
evidence to date (6, 7, 47, 48) together with the current observations suggest
that heavy chain-loss mutants will prove most frequent and troublesome. They
pose a particular problem because the loss ofsurface Ig means that a completelyGLENNIE ET AL.
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new tumor-associated target antigen must be sought to attack these variants . The
idiotype-loss variants are potentially less troublesome because, as we have shown
in the current work, while the surface Ig remains on a tumor, it should be
possible to generate anti-Id antibodies or perhaps groups of antibodies that cover
the complete spectrum of expressed idiotype.
Summary
The potency and specificity of immunotoxins consisting of monoclonal anti-
idiotype conjugated to the ribosome-inactivating protein, saporin, have been
evaluated in the treatment of guinea pig L2C B lymphocytic leukemia. The
immunotoxins were therapeutically much more effective than their parent anti-
bodies. Their specificity reflected that of their antiidiotype component. Although
the leukemia emerged eventually in most animals treated with these conjugates,
most of the cells showed altered Ig expression, which rendered them resistant to
the therapy. Commonly, the emerging cells had lost /. heavy chain production,
leaving them negative for intracellular, surface, and secreted IgM, but still
positive for X light chain production. In addition, a minor group of L2C variants
was identified in a protocol designed to detect mutants at very low frequency:
here the cells were exposed in vitro to immunotoxin and, while still viable as
judged by dye-exclusion, inoculated in large numbers into animals. In tumor
that emerged under these circumstances, the majority of cells were again im-
munoglobulin-negative; however a minority exhibited IgM with an altered idi-
otype (Idiotope-loss variants), rendering them unreactive with immunotoxin.
Immunotherapy with unmodified anti-Id antibody alone does not reveal these
variants, and we suggest it is the increased selective force exerted by the highly
potent immunotoxins that allow these minor nonreactive populations to emerge.
We are indebted to many colleagues for discussion, in particular F. K. Stevenson, A. L.
Tutt, A. George, and P. Alexander; to J . Illston andJ. Greenman for technical assistance,
and to M. Caddy for help in preparation of the manuscript.
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